The weight-loss drug with huge growth potential

episode

Short Briefings on Long Term Thinking - Baillie Gifford not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Short Briefings on Long Term Thinking - Baillie Gifford

SpaceX: past, present, future – and finding the next world-changers 36 min · 04 Aug 2026

Tokenisation: a better way to own what you own 31 min · 23 Jun 2026

Why American culture feels so chaotic – and how investors can benefit 36 min · 01 Jun 2026

All episodes from Short Briefings on Long Term Thinking - Baillie Gifford →

Report any issue

Source

Recorded07 Feb 2024

Publisherfeeds.blubrry.com ↗

Handlerec:13479953

Show notes

A new medicine that can help patients lose 15 per cent of their body weight could have far-reaching consequences for healthcare. Wegovy mimics a hormone the gut releases, reducing appetite and slowing digestion to delay hunger’s return. Research is also underway into other potential health benefits. In this podcast, Baillie Gifford investment manager Ross Mathison discusses its maker, the Danish pharmaceuticals manufacturer Novo Nordisk, which became Europe’s most valuable company in 2023. Background:Ross Mathison is an investment manager in our Global Income Growth Team, co-manager of our Global Income Growth Fund and deputy manager of the Scottish American Investment Company (SAINTS). In this episode of Short Briefings on Long Term Thinking, he discusses how medicines that mimic the glucagon-like peptide-1 (GLP-1) hormone could help tackle the growing problem of weight gain. Forecasts suggest that by 2035, more than half the world’s population will either be overweight or obese. That’s likely to lead to more people suffering associated diseases, putting health budgets under further strain. Novo Nordisk initially researched GLP-1s as a diabetes treatment. The company is the world’s biggest insulin producer, but it’s the release of its weight-loss drug Wegovy that’s transformed its growth prospects. News that medical trials suggest that the therapy could also reduce the likelihood of heart attacks, strokes and other cardiovascular threats among some patients has driven further investor interest. Mathison explains that there could be further health benefits beyond this, how even more effective treatments could follow and why Novo Nordisk’s manufacturing edge and connection to the world’s biggest charitable foundation bode well for its future. Resources:New England Journal of Medicine: Semaglutide trialNovo Nordisk cardiovascular trial press releaseNovo Nordisk kidney trial press releaseNovo Nordisk FoundationWegovyWorld Health Organization obesity factsheetHitting Against the Spin Timecodes:00:00 Introduction1:40 What are GLP-1s?4:00 Scientific breakthrough5:05 Obesity: a disease, not a choice6:45 Novo Nordisk’s drug, Wegovy08:10 Prescription costs

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.